Table 2 Cancer risk for T2DM patients by sex and cancer site

Head & Neck

[C00-C14; C30-C32]

2

0.40

(0.05, 1.46)

14

0.75

(0.41, 1.26)

Stomach

[C16]

10

1.07

(0.51, 1.97)

8

0.55

(0.24, 1.08)

Colorectum

[C18-C21]

27

0.94

(0.62, 1.36)

44

1.11

(0.81, 1.49)

Liver

[C22]

7

2.40

(0.96, 4.94)

20

2.71

(1.65, 4.18)

Pancreas

[C25]

16

1.78

(1.02, 2.89)

18

1.87

(1.11, 2.96)

Lung

[C33-C34]

15

0.79

(0.44, 1.30)

45

0.92

(0.67, 1.24)

Melanoma

[C43]

9

0.82

(0.37, 1.55)

11

0.70

(0.35, 1.25)

Breast

[C50]

72

1.13

(0.88, 1.42)

Breast postmenopausal

[C50]

70

1.18

(0.92, 1.49)

Cervix uteri

[C53]

10

1.81

(0.87, 3.32)

Corpus uteri

[C54]

24

1.79

(1.15, 2.66)

Ovary

[C56]

7

0.63

(0.25, 1.29)

Prostate

[C61]

83

0.85

(0.68, 1.05)

Bladder

[C67]

4

0.89

(0.24, 2.29)

16

1.10

(0.63, 1.79)

Kidney

[C64-C65]

10

1.45

(0.70, 2.67)

19

1.65

(0.99, 2.57)

Brain

[C47; C70-C72]

0

0

(0.00, 1.18)

3

0.73

(0.15, 2.13)

Thyroid

[C73]

8

1.65

(0.71, 3.25)

1

0.30

(0.01, 1.67)

Haem&Lymph¹⁾

[C81-C85; C88; C90-C96; D45-D47]

26

1.28

(0.84, 1.87)

21

0.78

(0.48, 1.18)

All cancer sites except NMSC

[C00-C97; D45-D47; exc. C44]

234

1.05

(0.92, 1.20)

291

0.93

(0.82, 1.04)